429672-02-6

Basic information

• Product Name: 1-Boc-3-azido-azetidine
• Synonyms: 1-Boc-3-azido-azetidine;tert-butyl 3-azidoazetidine-1-carboxylate
• CAS NO: 429672-02-6
• Molecular Formula: C₈H₁₄N₄O₂
• Molecular Weight: 198.22236
• Mol File: 429672-02-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Boc-3-azido-azetidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-3-azido-azetidine(429672-02-6)
• EPA Substance Registry System: 1-Boc-3-azido-azetidine(429672-02-6)

Safety Data

• Hazardous Substances Data: 429672-02-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-3-azido-azetidine is used as a reactant for the preparation of cyanoazetidines, cyanopyrrolidines, and their analogs. These compounds serve as inhibitors of cathepsin, an enzyme family involved in various physiological processes, including protein degradation and immune response. By inhibiting cathepsin, these compounds can potentially be used in the treatment of various diseases, such as cancer and autoimmune disorders.
Additionally, 1-Boc-3-azido-azetidine and its derivatives can be used as antiosteoporotic agents. Osteoporosis is a bone disease characterized by low bone mass and increased bone fragility, leading to a higher risk of fractures. 1-Boc-3-azido-azetidines derived from 1-Boc-3-azido-azetidine may help in the development of new therapeutic strategies to combat osteoporosis by targeting specific pathways involved in bone metabolism and maintaining bone health.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 141699-58-3 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 193269-78-2 3-aminoazetidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY

The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS

Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.

N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Aminothiazole compounds with N-containing cycloalkyl at the 2-amino position which are represented by the Formula (I), or a pharmaceutically acceptable prodrug of said compound, or pharmaceutically acceptable salt of said compound, modulate and/or inhibit the cell proliferation and activity of protein kinases.

1-METHYLCARBAPENEM DERIVATIVES

The present invention relates to 1-methylcarbapenem compounds having excellent antibacterial activity, pharmacologically acceptable ester derivatives thereof, pharmacologically acceptable salts thereof, pharmaceutical compositions (particularly antibacterial agents) containing them as active ingredient, use of the compounds, ester derivatives or salts thereof for preparing such pharmaceutical compositions and a method of preventing or treating diseases (particularly bacterial infections) in which a pharmacologically effective amount of the compound, ester derivative or salt is administered to a warm-blooded animal (particularly a human being). The 1-methylcarbapenem compounds of the present invention are represented by the general formula (I): wherein:R1 is a group represented by the formula COOR3 (wherein R3 represents a hydrogen atom, a C1-C6 alkyl group or the like), a group represented by the formula CONR4R5 (wherein R4 and R5 each independently represent a hydrogen atom, a C1-C6 alkyl group which may be substituted or the like), a cyano group, a group represented by the formula CH2OR6 (wherein R6 represents a hydrogen atom, a C1-C6 alkyl group or the like) or a group represented by the formula CH2NR7R8 (wherein R7 represents a hydrogen atom, a C1-C6 alkyl group or the like, and R8 represents a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1- C6 alkoxycarbonyl group or the like);R2 represents a hydrogen atom or a C1-C6 alkyl group;n represents 1, 2 or 3; andX represents a sulfur atom or an oxygen atom.

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.